October 7, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares over potential securities laws violations by Alnylam Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) concerning whether a series of statements by Alnylam Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) grew from $53.71 per share in August 2014 to as high as $138.73 per share in June 2015.

Alnylam Pharmaceuticals, Inc. reported that its annual Total Revenue declined from $50.56 million in 2014 to $41.10 million in 2015 while its respective Net Loss decreased from $360.39 million to $290.07 million.

On October 10, 2016, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALN)Y announced that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing, the Company has decided to discontinue development of revusiran, an investigational RNA interference (RNAi) therapeutic that was being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM).

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) declined to as low as $33.16 per share on October 7, 2016.